Yungjin Pharm. Co., Ltd.
Korea ExchangeTotal Valuation
Yungjin Pharm. Co., Ltd. carries a market capitalization of 223.13B, placing it among publicly traded companies globally. Its enterprise value stands at 396.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 223.13B |
| Enterprise Value | 396.88B |
Share Statistics
Yungjin Pharm. Co., Ltd. currently has 182.89M shares outstanding.
| Shares Outstanding | 182.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.25, and the price-to-book ratio stands at 4.56.
| PE Ratio | N/A |
| PS Ratio | 1.25 |
| PB Ratio | 4.56 |
| P/TBV Ratio | 3.67 |
| P/FCF Ratio | 119.33 |
| P/OCF Ratio | -39.19 |
Enterprise Valuation
On an enterprise value basis, Yungjin Pharm. Co., Ltd. trades at an EV/EBITDA multiple of 881.24 and an EV/FCF ratio of 68.87. The EV/Sales ratio of 1.56 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 881.24 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.56 |
| EV / EBITDA | 881.24 |
| EV / EBIT | 881.24 |
| EV / FCF | 68.87 |
Financial Position
Yungjin Pharm. Co., Ltd. maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 95.88, indicating elevated leverage, while an interest coverage ratio of 0.11 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.66 |
| Quick Ratio | 0.09 |
| Debt / Equity | 95.88 |
| Debt / EBITDA | 189.06 |
| Interest Coverage | 0.11 |
Financial Efficiency
| Return on Equity (ROE) | -4.82 |
| Return on Assets (ROA) | -1.48 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 2.12 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.72 |
Taxes
Over the trailing twelve months, Yungjin Pharm. Co., Ltd. has paid -956.63M in income taxes, reflecting an effective tax rate of 49.29.
| Income Tax | -956.63M |
| Effective Tax Rate | 49.29 |
Stock Price Statistics
Yungjin Pharm. Co., Ltd.'s stock has declined approximately -46.0177% over the past 52 weeks. The 50-day moving average sits at 1,424.62, while the 200-day moving average is 1,802.77.
| Beta (5Y) | N/A |
| 52-Week Price Change | -46.0177% |
| 50-Day Moving Average | 1,424.62 |
| 200-Day Moving Average | 1,802.77 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Yungjin Pharm. Co., Ltd. generated 253.94B in revenue and converted that into -3.49B in net income, yielding earnings per share of -18.81. EBITDA reached 450.37M, while operating income came in at 450.37M.
| Revenue | 253.94B |
| Gross Profit | 75.20B |
| Operating Income | 450.37M |
| Pretax Income | -4.44B |
| Net Income | -3.49B |
| EBITDA | 450.37M |
| EBIT | 450.37M |
| Earnings Per Share (EPS) | -18.81 |
Balance Sheet
Yungjin Pharm. Co., Ltd. holds 6.27B in cash and equivalents against 85.15B in total debt, resulting in a net debt position of 77.60B. Total book value stands at 69.67B, with working capital of 46.90B providing operational flexibility.
| Cash & Cash Equivalents | 6.27B |
| Total Debt | 85.15B |
| Net Debt | 77.60B |
| Equity (Book Value) | 69.67B |
| Book Value Per Share | 375.96 |
| Working Capital | 46.90B |
Cash Flow
Yungjin Pharm. Co., Ltd. produced -8.11B in operating cash flow over the past twelve months. After subtracting -10.78B in capital expenditures, free cash flow totaled -18.89B - equivalent to -101.95 per share.
| Operating Cash Flow | -8.11B |
| Capital Expenditures | -10.78B |
| Free Cash Flow | -18.89B |
| FCF Per Share | -101.95 |
Margins
Yungjin Pharm. Co., Ltd. operates with a gross margin of 29.61, reflecting its pricing power and cost economics. The operating margin of 0.18 and net profit margin of -1.37 provide insight into operational efficiency.
| Gross Margin | 29.61 |
| Operating Margin | 0.18 |
| Pretax Margin | -1.75 |
| Profit Margin | -1.37 |
| EBITDA Margin | 0.18 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.42 |
| FCF Yield | 0.84 |
Stock Splits
Yungjin Pharm. Co., Ltd.'s most recent stock split took place on June 18, 2010 with a 500:563 split ratio.
| Last Split Date | 6/18/2010 |
| Split Ratio | 500:563 |
Scores
Yungjin Pharm. Co., Ltd. posts an Altman Z-Score of 2.53, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.53 |